Support for people with diabetes, pre-diabetes & those at risk for diabetes.

John F. Burd, PhD

Chief Executive Officer

Dr. Burd has over 30 years of experience in glucose monitoring technology. Dr. Burd was the founder of DexCom, where he directed the company’s work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. DexCom has a market capitalization of more than $5 billion. Previously, Dr. Burd was CEO of Oculir, MiraMedica and LXN. Dr. Burd has authored and co-authored numerous articles and his work in the medical and biotechnology field has led to the filing and ownership of twenty-three patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.

John F. Burd, PhD – Chief Executive Officer

Michael Beeuwsaert

Chief Financial Officer

Mr. Beeuwsaert has over 25 years of experience as CEO or CFO in medical technology. He is a Partner at Novus Medical Ventures. Previously, he was Founder & CEO of Numira, a CRO with patented imaging technology. Prior to Numira, he served as CEO of Alerion, a life science tool company. Prior to that, Mr. Beeuwsaert was the CFO, then CEO at LXN, a company with innovative devices for controlling diabetes. After filing for an IPO, LXN was acquired by a market leader. Prior to LXN, he served as CFO at Ansys Diagnostics. Mr. Beeuwsaert received a BA in Accounting from California State University, Fullerton and an MBA from Pepperdine University.

Michael Beeuwsaert – Chief Financial Officer

Vivianne Noetzel

Chief Regulatory Officer

Ms. Noetzel has over 30 years of experience in the medical device industry. Ms. Noetzel was Vice President of Research and Clinical/Regulatory Affairs of LXN Corporation, Applied Biotech Corporation and held several management positions at Quidel Corporation. Vivianne Noetzel started her own company, Noetzel Terratech over 10 years ago. Noetzel Terratech specializes in Clinical/Regulatory Affairs and counts several local and international clients including Occulir, Inc., Qualigen, Inc., DexCom, Inc. Ms. Noetzel started as a bench scientist at the SALK Institute. Ms. Noetzel has a Bachelor of Arts Degree in Biochemistry as well as undergraduate degrees in Organic Chemistry and Spanish Literature from the University of California, San Diego.

Vivianne Noetzel – Vice President, Clinical and Regulatory Affairs

Michael Walsh


Mr. Walsh has over 30 years of experience in the life sciences. Mr. Walsh founded Proprius Pharmaceuticals and was its President and CEO from its founding until it was acquired by Cypress Bioscience. Prior to establishing Proprius, Mr. Wals was a founder and President, CEO, and Executive Chairman at Prometheus Laboratories, Inc., a specialty pharmaceutical company. Previously, Mr. Walsh held executive positions with Quidel and La Jolla Pharmaceutical Company. Mr. Walsh has a Bachelor of Science degree from the University of Notre Dame and an M.B.A. from Pepperdine University.